US Stock MarketDetailed Quotes

BVS Bioventus

Watchlist
  • 10.440
  • -0.190-1.79%
Close Jan 3 16:00 ET
  • 10.210
  • -0.230-2.20%
Pre 05:27 ET
682.44MMarket Cap-17.11P/E (TTM)

Bioventus Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Bioventus Q3 2024 Earnings Date

Currency：USDNov 5, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
133.24M
138.96M
+5.73M
Beat Est.
+10.30%
+15.04%
+4.30%
EPS
-0.16
-0.07
+0.09
Beat Est.
-37.53%
+41.67%
+57.55%
Analyst Rating
Buy

Jan 5, 2025

Bioventus Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 138.666M--
--2024/Q4-- / 145.162M--
Nov 5, 20242024/Q3138.964M / 133.238M--
Aug 6, 20242024/Q2151.217M / 137.595M--
May 7, 20242024/Q1129.457M / 118.380M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 138.666M--
--2024/Q4-- / 145.162M--
Nov 5, 20242024/Q3138.964M / 133.238M--
Aug 6, 20242024/Q2151.217M / 137.595M--
May 7, 20242024/Q1129.457M / 118.380M--

Unlock Free Earnings Estimates

Bioventus Earnings Reports

  • Bioventus | 10-Q: Q3 2024 Earnings Report

    Nov 5, 2024 07:41 ET

  • Bioventus | 8-K: Bioventus Reports Third Quarter Financial Results

    Nov 5, 2024 07:36 ET

  • Bioventus | 10-Q: Q2 2024 Earnings Report

    Aug 6, 2024 07:53 ET

  • Bioventus | 8-K: Bioventus Reports Second Quarter Financial Results

    Aug 6, 2024 07:43 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    DexCom
    DXCM
    +3.27%
    Collegium Pharmaceutical
    COLL
    +3.07%
    Lantheus
    LNTH
    +2.71%
    Cars.com
    CARS
    +1.72%
    YETI Holdings
    YETI
    +1.60%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Jan 5, 2025

    Buy

    • Buy

      66.67%

    • Hold

      33.33%

    • Sell

      0.00%

    Price Target

    No Data